129.6K XNAS Volume
XNAS 25 Mar, 2025 4:00 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 222,543 | 222,543 | - | - | Restricted Stock Units | |
| Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 333,815 | 333,815 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 87,845 | 87,845 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 58,563 | 58,563 | - | - | Restricted Stock Units | |
| Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 85,895 | 85,895 | - | - | Stock Option (Right to Buy) | |
| Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 57,263 | 57,263 | - | - | Restricted Stock Units | |
| Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 39,000 | 39,000 | - | - | Restricted Stock Units | |
| Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,350 | 73,350 | - | - | Stock Option (Right to Buy) | |
| Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 58,500 | 58,500 | - | - | Stock Option (Right to Buy) | |
| Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,350 | 73,350 | - | - | Stock Option (Right to Buy) | |
| Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 25,107 | 242,591 | - | 0.6 | 14,108 | Common Stock |
| Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 108,333 | 267,698 | - | 0 | Common Stock | |
| Mark J. Litton | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 108,333 | 216,667 | - | - | Restricted Stock Units | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 8,510 | 130,761 | - | 0.6 | 4,782 | Common Stock |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 139,271 | - | 0 | Common Stock | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.55 per share. | 31 Dec 2024 | 9,920 | 102,604 | - | 0.6 | 5,456 | Common Stock |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 73,333 | - | - | Restricted Stock Units | |
| Mark Worthington | General Counsel and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 73,333 | - | - | Restricted Stock Units | |
| Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.55 per share. | 31 Dec 2024 | 3,651 | 55,578 | - | 0.5 | 2,008 | Common Stock |
| Mark Worthington | General Counsel and CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 36,667 | 92,245 | - | 0 | Common Stock | |
| Mark Worthington | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 8,510 | 83,735 | - | 0.6 | 4,782 | Common Stock |
| Robert Renninger | VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 12,359 | 92,605 | - | 0 | Common Stock | |
| Robert Renninger | VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 12,359 | 24,718 | - | - | Restricted Stock Units | |
| Robert Renninger | VP of Finance | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 2,881 | 89,724 | - | 0.6 | 1,619 | Common Stock |
| Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.55 per share. | 31 Dec 2024 | 3,651 | 80,246 | - | 0.5 | 2,008 | Common Stock |
| Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2024 | 325,000 | 325,000 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Restricted Stock Units | |
| Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Restricted Stock Units | |
| Mark Worthington | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 37,077 | 37,077 | - | - | Stock Option (Right to Buy) | |
| Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 37,077 | 37,077 | - | - | Restricted Stock Units | |
| Andrew Gengos | CFO and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 03 Sep 2024 | 10,000 | 93,804 | - | 1.3 | 13,400 | Common Stock |
| Andrew Gengos | CFO and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 1,272 | 97,532 | - | 0.6 | 720 | Common Stock |
| Andrew Gengos | CFO and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 5,000 | 98,804 | - | 0 | Common Stock | |
| Mark J. Litton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 20,000 | 164,397 | - | 0 | Common Stock | |
| Mark J. Litton | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 5,032 | 159,365 | - | 0.6 | 2,848 | Common Stock |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 03 Sep 2024 | 4,953 | 85,209 | - | 1.3 | 6,637 | Common Stock |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 2,525 | 92,684 | - | 0.6 | 1,429 | Common Stock |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 95,209 | - | 0 | Common Stock | |
| Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 03 Sep 2024 | 10,000 | 44,452 | - | 1.3 | 13,400 | Common Stock |
| Mark Worthington | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 2,525 | 51,927 | - | 0.6 | 1,429 | Common Stock |
| Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 54,452 | - | 0 | Common Stock | |
| Rachel Lenington | COO and CDO | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 2,525 | 20,870 | - | 0.6 | 1,429 | Common Stock |
| Rachel Lenington | COO and CDO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 23,395 | - | 0 | Common Stock | |
| Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 2.26 per share. | 21 Jun 2024 | 15,000 | 53,315 | - | 2.3 | 33,872 | Common Stock |
| Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 2.42 per share. | 21 Jun 2024 | 27,400 | 80,715 | - | 2.4 | 66,179 | Common Stock |
| James A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Grant E. Pickering | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Michael A. Panzara | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Barbara Kosacz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Mark Litton J. | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Church Kevin | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Gengos Andrew | CFO AND CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 280,000 | 280,000 | - | - | Stock Option (Right to Buy) | |
| Rachel Lenington | COO AND CDO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 82,668 | - | 0 | Common Stock | |
| Gengos Andrew | See Below | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 5,000 | 85,012 | - | 0 | Common Stock | |
| Mark Worthington | General Counsel | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 34,452 | - | 2.9 | 7,019 | Common Stock |
| Worthington Mark | General Counsel | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 7,767 | 26,864 | - | 2.4 | 18,718 | Common Stock |
| Mark Litton J. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 4,820 | 144,397 | - | 2.9 | 14,026 | Common Stock |
| Andrew Gengos | See Below | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 1,208 | 83,804 | - | 2.9 | 3,515 | Common Stock |
| Litton Mark J. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,000 | 149,217 | - | 0 | Common Stock | |
| Worthington Mark | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 36,864 | - | 0 | Common Stock | |
| Church Kevin | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 04 Jan 2024 | 3,397 | 72,668 | - | 1.3 | 4,552 | Common Stock |
| Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 91,482 | - | 0 | Common Stock | |
| Kevin Church | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 809 | 69,271 | - | 2.4 | 1,950 | Common Stock |
| Rachel Lenington | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 13,395 | - | 2.9 | 7,019 | Common Stock |
| Kevin Church | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 80,256 | - | 2.9 | 7,019 | Common Stock |
| Lenington Rachel | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 15,807 | - | 0 | Common Stock | |
| Gengos Andrew | CFO AND CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 1,208 | 83,804 | - | 2.9 | 3,515 | Common Stock |
| J. Litton Mark | Director, CEO | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 4,820 | 144,397 | - | 2.9 | 14,026 | Common Stock |
| Church Kevin | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 80,256 | - | 2.9 | 7,019 | Common Stock |
| Worthington Mark | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 7,767 | 26,864 | - | 2.4 | 18,718 | Common Stock |
| Mark Worthington | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 36,864 | - | 0 | Common Stock | |
| Lenington Rachel | COO AND CDO | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 13,395 | - | 2.9 | 7,019 | Common Stock |
| Andrew Gengos | CFO AND CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 5,000 | 85,012 | - | 0 | Common Stock | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 82,668 | - | 0 | Common Stock | |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 04 Jan 2024 | 3,397 | 72,668 | - | 1.3 | 4,552 | Common Stock |
| Lenington Rachel | COO AND CDO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 15,807 | - | 0 | Common Stock | |
| Mark J. Litton | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,000 | 149,217 | - | 0 | Common Stock | |
| Worthington Mark | GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 2,412 | 34,452 | - | 2.9 | 7,019 | Common Stock |
| Church Kevin | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 04 Jan 2024 | 809 | 69,271 | - | 2.4 | 1,950 | Common Stock |
| Gengos Andrew | See Below | Purchase of securities on an exchange or from another person at price $ 3.40 per share. | 07 Jun 2023 | 2,859 | 68,293 | - | 3.4 | 9,721 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.44 per share. | 07 Jun 2023 | 11,719 | 80,012 | - | 3.4 | 40,308 | Common Stock |
| Gengos Andrew | See Below | Purchase of securities on an exchange or from another person at price $ 3.36 per share. | 07 Jun 2023 | 422 | 65,434 | - | 3.4 | 1,417 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 02 Jun 2023 | 15,000 | 35,012 | - | 3 | 45,000 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 2.94 per share. | 02 Jun 2023 | 3,418 | 20,012 | - | 2.9 | 10,066 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 2.86 per share. | 02 Jun 2023 | 6,582 | 16,594 | - | 2.9 | 18,823 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 2.75 per share. | 02 Jun 2023 | 10,012 | 10,012 | - | 2.8 | 27,533 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.02 per share. | 02 Jun 2023 | 10,000 | 65,012 | - | 3.0 | 30,154 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 02 Jun 2023 | 10,000 | 55,012 | - | 3.0 | 29,999 | Common Stock |
| Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 02 Jun 2023 | 10,000 | 45,012 | - | 3.0 | 29,997 | Common Stock |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2023 | 7,882 | 0 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 02 Jun 2023 | 7,882 | 81,482 | - | 1.4 | 10,641 | Common Stock |
| Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 02 Jun 2023 | 7,764 | 73,600 | - | 2.4 | 18,711 | Common Stock |
| James A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Grant E. Pickering | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Michael A. Panzara | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Barbara Kosacz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Andrew Gengos | See Below | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 400,000 | 400,000 | - | - | Stock Options (right to buy) | |
| James A. Johnson | Director | Purchase of securities on an exchange or from another person at price $ 2.40 per share. | 29 Mar 2023 | 5,000 | 5,000 | - | 2.4 | 12,000 | Common Stock |
| Grant E. Pickering | Director | Purchase of securities on an exchange or from another person at price $ 2.47 per share. | 29 Mar 2023 | 15,000 | 25,783 | - | 2.5 | 37,050 | Common Stock |
| Grant E. Pickering | Director | Purchase of securities on an exchange or from another person at price $ 2.33 per share. | 29 Mar 2023 | 10,000 | 10,783 | - | 2.3 | 23,300 | Common Stock |
| Kevin Church | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 24 Mar 2023 | 6,410 | 68,462 | - | 1.4 | 8,654 | Common Stock |
| Kevin Church | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2023 | 6,410 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 2.74 per share. | 27 Jan 2023 | 662 | 129,217 | - | 2.7 | 1,814 | Common Stock |
| Glenna Mileson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 2.74 per share. | 19 Jan 2023 | 657 | 62,052 | - | 2.7 | 1,800 | Common Stock |
| Mark Worthington | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Rachel Lenington | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 3.29 per share. | 02 Dec 2022 | 30,000 | 38,315 | - | 3.3 | 98,700 | Common Stock |
| Hans Moebius | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 3.29 per share. | 15 Nov 2022 | 5,000 | 65,836 | - | 3.3 | 16,442 | Common Stock |
| Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 3,700 | 6,410 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 28 Oct 2022 | 3,700 | 61,395 | - | 1.4 | 4,995 | Common Stock |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 13 Oct 2022 | 7,881 | 60,836 | - | 1.3 | 10,639 | Common Stock |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 7,881 | 7,882 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 2.88 per share. | 28 Jun 2022 | 10,000 | 52,955 | - | 2.9 | 28,800 | Common Stock |
| Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 08 Jun 2022 | 2,500 | 50,309 | - | 1.4 | 3,375 | Common Stock |
| Kevin Church | Executive VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 2,500 | 10,110 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 7.06 per share. | 08 Jun 2022 | 243 | 47,809 | - | 7.1 | 1,716 | Common Stock |
| James A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 13,871 | 13,871 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 13,871 | 13,871 | - | - | Stock Option (Right to Buy) | |
| Grant E. Pickering | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 3,467 | 3,467 | - | - | Stock Option (Right to Buy) | |
| Michael A. Panzara | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 2,311 | 2,311 | - | - | Stock Option (Right to Buy) | |
| Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 13,871 | 13,871 | - | - | Stock Option (Right to Buy) | |
| Barbara Kosacz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 13,871 | 13,871 | - | - | Stock Option (Right to Buy) | |
| Glenna Mileson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2022 | 3,000 | 167,000 | - | - | Stock Option (right to buy) | |
| Glenna Mileson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.64 per share. | 12 Apr 2022 | 3,000 | 100,060 | - | 10.6 | 31,920 | Common Stock |
| Kelly A. Romano | Director | Purchase of securities on an exchange or from another person at price $ 13.11 per share. | 31 Mar 2022 | 8,000 | 8,315 | - | 13.1 | 104,880 | Common Stock |
| Michael A. Panzara | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2022 | 27,742 | 27,742 | - | - | Stock Option (Right to Buy) | |
| Grant E. Pickering | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 27,742 | 27,742 | - | - | Stock Option (Right to Buy) | |
| Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Litton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 27 Jan 2022 | 885 | 115,758 | - | 12.5 | 11,071 | Common Stock |
| Glenna Mileson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 18 Jan 2022 | 829 | 31,256 | - | 12.5 | 10,371 | Common Stock |
| Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Executive VP, Research | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 18 Jan 2022 | 96 | 44,414 | - | 12.5 | 1,201 | Common Stock |
| Mark Worthington | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Rachel Lenington | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Glenna Mileson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 04 Jan 2022 | 6,305 | 97,060 | - | 1.4 | 8,512 | Common Stock |
| Glenna Mileson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 6,305 | 0 | - | - | Stock Option (Right to Buy) | |
| Glenna Mileson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 04 Jan 2022 | 931 | 90,755 | - | 12.5 | 11,647 | Common Stock |
| Mark J. Litton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 17 Aug 2021 | 867 | 64,433 | - | 14.4 | 12,528 | Common Stock |
| Mark J. Litton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 50,440 | 100,880 | - | - | Stock Option (Right to Buy) | |
| Mark J. Litton | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 17 Aug 2021 | 50,440 | 114,873 | - | 1.4 | 68,094 | Common Stock |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 21 Jul 2021 | 15,762 | 30,427 | - | 1.4 | 21,279 | Common Stock |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2021 | 15,762 | 15,763 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2021 | 12,610 | 0 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 21 Jul 2021 | 12,610 | 14,665 | - | 1.4 | 17,024 | Common Stock |
| Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 21 Jul 2021 | 2,055 | 2,055 | - | 14.5 | 29,695 | Common Stock |
| John M. Fluke | Director | Other type of transaction at price $ 0.00 per share. | 15 Jun 2021 | 3,000 | 3,731 | - | 0 | Common Stock | |
| John M. Fluke | Director | Other type of transaction at price $ 0.00 per share. | 15 Jun 2021 | 1,000 | 144,884 | - | 0 | Common Stock | |
| James A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 13,871 | 13,871 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 13,871 | 13,871 | - | - | Stock Option (Right to Buy) | |
| Glenna Mileson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 18 May 2021 | 6,305 | 89,824 | - | 1.4 | 8,512 | Common Stock |
| Glenna Mileson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 18 May 2021 | 1,554 | 83,519 | - | 14.4 | 22,455 | Common Stock |
| Glenna Mileson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 6,305 | 6,305 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Vice President of Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 3,152 | 0 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Vice President of Discovery | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 18 May 2021 | 185 | 41,166 | - | 14.4 | 2,673 | Common Stock |
| Kevin Church | Vice President of Discovery | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 18 May 2021 | 3,152 | 44,318 | - | 1.0 | 3,278 | Common Stock |
| Barbara Kosacz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 27,742 | 27,742 | - | - | Stock Option (Right to Buy) | |
| Mark J. Litton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Leen Kawas | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 231,000 | 231,000 | - | - | Stock Option (Right to Buy) | |
| Glenna Mileson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 73,500 | 73,500 | - | - | Stock Option (Right to Buy) | |
| Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Kevin Church | Vice President of Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 03 Feb 2021 | 3,783 | 143,884 | - | 1.3 | 5,107 | Common Stock |
| John M. Fluke | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 3,783 | 0 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 25,220 | 0 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.19 per share. | 03 Feb 2021 | 25,220 | 140,101 | - | 1.2 | 30,012 | Common Stock |
| Kelly A. Romano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 27,742 | 27,742 | - | - | Stock Option (Right to Buy) | |
| John M. Fluke | Director | 22 Sep 2020 | 6,731 | 0 | - | - | Series B-1 Preferred Stock | ||
| John M. Fluke | Director | 22 Sep 2020 | 51,831 | 0 | - | - | Series A-1 Preferred Stock | ||
| John M. Fluke | Director | 22 Sep 2020 | 12,610 | 0 | - | - | Series A Preferred Stock | ||
| John M. Fluke | Director | 22 Sep 2020 | 6,731 | 6,731 | - | 0 | Common Stock | ||
| John M. Fluke | Director | 22 Sep 2020 | 12,610 | 63,050 | - | 0 | Common Stock | ||
| John M. Fluke | Director | 22 Sep 2020 | 51,831 | 114,881 | - | 0 | Common Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 0 | - | - | Series B-1 Preferred Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 13,126 | 0 | - | - | Series B Preferred Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 6,563 | - | 0 | Common Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 6,563 | - | 0 | Common Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 6,563 | - | 0 | Common Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 13,126 | 63,566 | - | 0 | Common Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 0 | - | - | Series B-1 Preferred Stock | ||
| Mark J. Litton | Chief Operating Officer | 22 Sep 2020 | 6,563 | 0 | - | - | Series B-1 Preferred Stock |